Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 5/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606330 | 0.94 | HPGD (0.61) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL6105130 | 0.85 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL16604392 | 0.85 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL20353737 | 0.84 | HPGD (0.59) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL1002397 | 0.84 | HPGD (0.59) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL14622828 | 0.84 | HPGD (0.59) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| Methylene Chloride SCHEMBL27882742 | 0.84 | HPGD (0.59) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL30258893 | 0.83 | NR1H2 (0.51) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL2006303 | 0.83 | HPGD (0.65) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL21994463 | 0.83 | HPGD (0.57) | HPGDRECQLPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061759-B1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2061759-B1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8324251-B2 | Cyclic modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324251-B2 | Cyclic modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324251-B2 | Cyclic modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-7557104-B2 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557104-B2 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-07-07 | — | — | US | disclosed |
| EP-2061759-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Brystol-Myers Squibb Company (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042926-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042926-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080027063-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-20080027063-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027063-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | CHEK1, CHEK2, CDKN1A | HPGD 3423/4885RECQL 1008/4885PTPN2 182/4885 |
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CXCR1, CCR3 | HPGD 1182/4885RECQL 1120/4885PTPN2 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.